AxoGen Revenue and Competitors

Claim your profile

Alachua, FL USA

Location

$69.9M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • AxoGen's estimated annual revenue is currently $83.9M per year.(i)
  • AxoGen received $41.0M in venture funding in November 2017.
  • AxoGen's estimated revenue per employee is $177,457
  • AxoGen's total funding is $69.9M.

Employee Data

  • AxoGen has 473 Employees.(i)
  • AxoGen grew their employee count by 2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4M6343%N/AN/A
#2
$2M13N/AN/AN/A
#3
$3.6M576%N/AN/A
#4
$17.5M11320%N/AN/A
#5
$3.1M200%N/AN/A
#6
$3.5M260%$98.8MN/A
#7
$28.5M1847%N/AN/A
#8
$16.6M10722%N/AN/A
#9
$3.7M24118%N/AN/A
#10
$8.8M5784%N/AN/A

It's time to rethink nerve repair! AxoGen (NASDAQ: AXGN) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. People suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. Damage may cause loss of function and feeling. AxoGen is bringing the science of nerve repair to life with its Avance® Nerve Graft which AxoGen believes is the first and only commercially available allograft for bridging nerve discontinuities, AxoGuard® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard® Nerve Protector that protects nerves during the healing process.

keywords:Biotechnology,E-Commerce,Healthcare,Medical Devices,Pharmaceuticals

$69.9M

Total Funding

473

Number of Employees

$83.9M

Revenue (est)

2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

AxoGen News

2022-04-17 - Electromed (NYSE:ELMD) versus AxoGen (NASDAQ:AXGN ...

Electromed (NYSE:ELMD) versus AxoGen (NASDAQ:AXGN) Critical Analysis. Posted by admin on Apr 18th, 2022. Share on Twitter Share on Facebook Share on...

2022-04-17 - Analysts Expect AxoGen, Inc. (NASDAQ:AXGN) to Post -$0.17 ...

AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves.

2022-04-13 - Axogen, Inc. to Report First Quarter 2022 Financial Results ...

Axogen management will host an investment-community conference call and webcast following the release at 4:30 p.m. ET.

2019-09-08 - AxoGen, Inc (NASDAQ:AXGN) Director Acquires $217645.35 ...

AxoGen, Inc (NASDAQ:AXGN) Director Quentin S. Blackford bought 15,535 shares of AxoGen stock in a transaction that occurred on Monday, ...

2019-09-07 - Axogen to Participate in the 74th Annual American Society for ...

Axogen is an elite partner for the meeting and will host a lunch symposium and panel discussion on Friday, September 6 from 12:00 – 1:00 p.m. ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$144.3M575-8%N/A

AxoGen Funding

DateAmountRoundLead InvestorsReference
2006-03-03$7.8MBSpringboardArticle
2007-12-05$12.1MCMultipleArticle
2009-09-21$2.6MDArticle
2010-01-27$3.4MUndisclosedArticle
2012-10-10$20.8MUndiclosedJMP SecuritiesArticle
2014-11-17$28.6MUndisclosedOberlandArticle
2015-02-06$UndisclosedUndisclosedArticle
2017-11-17$41.0MUndisclosedLeerink PartnersArticle